14th February|Commercial Media

Next generation microbiome weight management product reduces hunger and food cravings leading to weight loss

OptiBiotix Health Plc. (OptiBiotix), a leading life sciences business focused on harnessing the power of the human microbiome has completed a human study on its award-winning weight management ingredient SlimBiome®. The study demonstrated that human volunteers taking SlimBiome had statistically significant reductions in hunger and food cravings leading to weight loss and improved mood. These effects appear to be mediated by changes in gut bacteria, notably the relative abundance of Christensenellaceae, Bacteroidetes and Actinobacteria, bacteria within the gut microbiome associated with weight loss.

The study, carried out by leading scientists in the microbiome field, investigated the effect of SlimBiome, as the functional ingredient in the GoFigure® diet plan, on weight loss, satiety, satiation, mood and gut microbiome composition in a human intervention study. During the 4-week study, 12 otherwise healthy, overweight and obese females (18-65 years, BMI 25-35kg/m2) were asked to consume 9g SlimBiome daily delivered through the GoFigure diet plan.

After 4 weeks, statistically significant reductions were observed in weight, BMI, fat mass, hip circumference, percentage body fat, fat mass and systolic blood pressure. Not only that, but cravings for savoury foods were substantially reduced, accompanied by a significant improvement in mood.
Backed by randomised, double-blind, placebo-controlled human studies, SlimBiome has been developed by leading UK Universities to promote weight loss and has recently received medical device status and a CE mark. The product’s new status enables OptiBiotix to make medicinal or medical claims about SlimBiome where supported by clinical studies, extending the application of the award-winning ingredient from food products in to high-value medical products.

Stephen O’Hara, OptiBiotix CEO, said: “This study adds further evidence to other clinical studies and consumer feedback which shows SlimBiome has a significant impact on food cravings and hunger, leading to easier and more successful weight loss, typically 2-3lbs per week. Uniquely, this study shows weight loss is associated with significant changes in the microbiome.

“The presence of independent clinical studies, industry awards, and the approval of SlimBiome as a medical device with CE mark, should give consumers confidence in the safety and efficacy of SlimBiome to help weight loss. I believe functional ingredients like SlimBiome will increasingly help consumers to modify the type and amount of food they eat to manage their weight.”

The results of this study are being presented at Probiota 2019, a leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The abstracts and posters will also be available on https://optibiotix.com/publications/